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The  use of  limited  proteolysis  followed  by  peptide  mapping  for the  comparability  of  the  higher-order
structure  of  biopharmaceuticals  was  investigated.  In this  approach  the  proteolysis  is  performed  under
non-reducing  and  non-denaturing  conditions,  and  the  resulting  peptide  map  is determined  by the  sam-
ples primary  and  higher  order  structures.  This  allows  comparability  of biopharmaceuticals  to  be made in
terms  of their  higher  order  structure,  using  a method  that  is  relatively  simple  to implement.  The  diges-
tion  of  a monoclonal  antibody  under  non-denaturing  conditions  was  analyzed  using peptide  mapping,
circular  dichroism  (CD)  and  sodium  dodecyl  sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE).  This
allowed an  optimal  digestion  time  to be chosen.  This  method  was  then  assessed  for  its ability  to  detect
structural  change  using  a  monoclonal  antibody,  which  had been  subjected  to  a range  of stresses;  degly-
cosylation,  mild  denaturation  and  a batch  that  had  failed  speciﬁcations  due  to in-process  reduction.  Theircular dichroism
ass spectrometry
repeatability  and  inter-assay  precision  were  assessed.  It  was  demonstrated  that  the  limited  proteolysis
peptide  maps  of  the  three  stressed  samples  were  signiﬁcantly  different  to control  samples  and  that  the
differences  observed  were  consistent  between  the occasions  when  the assays  were  run.  A combination  of
limited  proteolysis  and CD or  SDS-PAGE  analysis  was  shown  to  enhance  the capacity  of these  techniques
to  detect  structural  change,  which  otherwise  would  not  have  been  observed.
©  2016  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Recombinant protein drugs are an increasing part of the phar-
aceutical landscape, with current market valued at over 100
illion dollars [1–4]. Monoclonal antibodies (mAbs) and increas-
ngly antibody drug conjugates (ADCs) are making an important
nd growing contribution to this class of drugs [2,5]. Biologic drugs
resent some unique analytical challenges as methods are required
or the analysis of the product’s primary and higher order structures
s well as their microheterogeneities [4,6–8]. The manufacture of
harmaceuticals is highly regulated [9] (cGMP) and the expecta-
ions of the regulatory agencies are increasing.
Abbreviations: ADC, antibody drug conjugate; F(ab)2, divalent fragment
ntigen binding; Fab, monovalent fragment antigen binding; mAb1-deg, degly-
osylated mAb1; mAb1-den, denatured mAb1; mAb1-r, reduced mAb1; NEM,
-ethylmaleimide.
∗ Corresponding author.
E-mail address: william.burkitt@ucb.com (W.  Burkitt).
1 Present address: Randall Division of Cell and Molecular Biophysics, King’s Col-
ege London, Guy’s Campus, London SE1 1UL, United Kingdom.
ttp://dx.doi.org/10.1016/j.jpba.2016.02.005
731-7085/© 2016 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Due to the inherent variability of biological drug production,
and despite the stringent controls during production, each batch
produced contains a range of isoforms of the desired product [7,8].
To ensure the safety of each batch, a range of testing is required
to ensure that the levels of these isoforms are within the expected
limits of the desired product [10]. Additionally the higher order
structure of the product has the potential to vary, which results in
a requirement for methods to assess this characteristic [6,8,11,12].
Assessment of higher order structure of a biopharmaceutical is stip-
ulated by ICH Q5(E) for characterization and comparability studies
[13]. The likelihood for uncharacteristic higher order structures
to be formed is increased when the product contains large struc-
tural modiﬁcation such as when the product is an ADC. There is
therefore a need for innovative techniques for the analysis and
characterization of the primary and higher order structure of bio-
pharmaceuticals.
For a protein/biologic drug to function as desired its higher order
structure must be correct. Failure of a biologic to adopt the cor-
rect higher order structure has undesirable consequences such as
lack of efﬁcacy, altered pharmacokinetics or immunogenicity [14].
It is therefore essential that the higher order structure of the bio-
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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ogic can be evaluated. This assessment is commonly undertaken
sing techniques such as circular dichroism (CD), [15–17]. Fourier
ransform infra-red (FTIR) spectroscopy or more recently hydro-
en/deuterium exchange mass spectrometry (HDX-MS) [12,18].
owever implementing acceptance criteria for these techniques
an be challenging.
Peptide mapping is a technique for the analysis of a protein’s
rimary structure, which is widely used in the biopharmaceuti-
al industry at all phases and levels of validation [19,20]. Peptide
apping typically involves denaturation, reduction and alkylation
f a sample followed by separation of the resulting peptides on a
eversed phase column with detection using either or both ultra
iolet (UV) absorbance or mass spectrometry (MS) detection. The
esulting chromatograms are unique to the sample, which allows
eptide mapping to be used as an identity test or for assessment
f comparability, either for lot release or characterization. Peptide
apping is a powerful technique for the detection of changes in
 protein’s primary structure, such as post translational modiﬁ-
ations (PTMs) or N/C-terminal extensions or truncations [4,21].
owever, as the sample is denatured prior to digestion, information
egarding the higher order structure is lost.
We investigated the use of limited proteolysis followed by pep-
ide mapping. Here, the proteolysis of a sample is performed under
on-denaturing and non-reducing conditions followed by separa-
ion of the sample on a reversed-phase column. As the digestion
akes place under non-denaturing conditions, the resulting chro-
atogram is determined both by the sample’s higher order and
rimary structures. It is similar in principle to limited proteolysis
22–24] and has parallels with the pulse proteolysis methodology
25].
To assess the applicability of this methodology the digestion
f two samples of the same antibody, one which had been deg-
ycosylated and one with the glycans intact, were monitored over
 time course using limited proteolysis peptide mapping with UV
nd mass spectrometry detection as well as CD and sodium dodecyl
ulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis.
his allowed the characteristics of the digestion to be investigated
s well as the optimum time for digestion to be determined. Once
he optimum time of digestion had been determined the repeata-
ility and intra assay precision were evaluated. The differences
etween peptide maps of samples were also evaluated. Finally
imited proteolysis with peptide mapping was applied to two addi-
ional samples, including a batch that failed to make speciﬁcations
r ‘real world’ sample. Comparison of the limited proteolysis with
eptide mapping results to those from CD and SDS-PAGE was  also
ade. The analysis of samples subjected to limited proteolysis fol-
owed by CD and SDS-PAGE was also investigated.
. Materials and methods
.1. Sample preparation
A fully humanized mAb  of the IgG4 subclass was used through-
ut this study; this is referred to throughout as mAb1. It was
roduced in-house using a GS-CHO cell line and was puriﬁed using
tandard antibody puriﬁcation procedures, including protein A,
nion exchange and cation exchange chromatography. Material
rom a batch of this product that failed to meet speciﬁcations was
lso used, this batch contained elevated levels of fragments with a
igh level of half antibody (halfmer).
The deglycosylated sample was prepared by incubation of 2 mgf mAb1 at 1 mg  mL−1 with 40 mU of PNGase F (N-Glycanase) from
ROzyme (Ely, Cambridgeshire, UK) at 37 ◦C for 18 h with 100 rpm
gitation on a New Brunswick Platform shaker. A control sam-
le was prepared alongside the deglycosylated sample with theiomedical Analysis 123 (2016) 162–172 163
exception that an equal volume of buffer rather than PNGase F was
added. The mildly denatured sample was prepared by diluting the
antibody to 1 mg  mL−1 in 2 M urea from Invitrogen (Paisley, Ren-
frewshire, UK) and 100 mM ammonium bicarbonate from Sigma
Aldrich (Gillingham, Dorset, UK) at pH 8.0. A control sample was
prepared alongside the mildly denatured sample with the excep-
tion that the urea was  omitted from the buffer.
2.2. Protease digestion
All samples were subjected to protease digestion by addition of
Endoproteinase Lys-C from Wako (Osaka, Japan) in 100 mM ammo-
nium hydrogen carbonate at pH 8.0 at 37 ◦C. The ratio of protein to
enzyme was  20:1 (w/w); the protein concentration during diges-
tion was 1 mg  mL−1. The digestion was  quenched by the addition
of formic acid from Fisher (Loughborough, Leicestershire, UK) to a
concentration of 5% by volume after the required time for the diges-
tion step had elapsed. For the time zero samples the addition of the
enzyme was immediately followed by the addition of the formic
acid.
2.3. Liquid chromatography-mass spectrometry (LC-MS)
Reverse-phase high performance liquid chromatography (RP-
HPLC) was performed using Waters Acquity chromatography
system coupled to quadrupole time-of-ﬂight mass spectrometer
(Xevo G2 QTOF) from Waters (Wilmslow, Cheshire, UK) using elec-
trospray ionization (ESI). 7.5 L (7.5 g of protein) of the digested
sample was  injected on a BEH300 C18 1.7 m 2.1 mm × 150 mm
column from Waters (Wilmslow, Cheshire, UK) with the column
oven maintained at 40 ◦C. The mobile phase has a ﬂow rate of
0.20 mL  min−1. The chromatography was  performed using water
from ROMIL (Cambridge, Cambridgeshire, UK) containing 0.1%
formic acid for mobile phase A and acetonitrile from ROMIL (Cam-
bridge, Cambridgeshire, UK) containing 0.1% formic acid for mobile
phase B as follows; B was  increased from 1% to 36% over 70 min  then
to 50% in 6 min  followed by a 4.5 min  at 90% B and a 7.5 min  equi-
libration period. The elution from the column was monitored by
absorbance at 214 nm with a photodiode array detector (Acquity
PDA) from Waters (Wilmslow, Cheshire, UK). The Xevo G2 QTOF
was operated in positive ion mode with a capillary voltage of 3.5 V
and a sample cone voltage of 35 V. Acquisitions were performed
over the range 50–2000 m/z  with a 1 s scan time. Lock mass calibra-
tion was performed using the monoisotopic peak of doubly charged
(Glu [1]) Fibrinopeptidase B human peptide from Sigma Aldrich
(Gillingham, Dorset, UK). Data analysis was performed with MassL-
ynx 4.1 from Waters (Wilmslow, Cheshire, UK) and BiopharmaLynx
1.3.3 Waters (Wilmslow, Cheshire, UK).
2.4. Circular dichroism
Near-UV spectra were recorded using a Chirascan Plus spec-
tropolarimeter. Data were collected at a scan rate of 0.5 nm s−1
over the range 250 nm to 320 nm for near UV CD using a cell path
length of 10 mm.  Digestion was  performed in device at 37 ◦C. Three
scans were acquired prior to digestion. The digestion was moni-
tored for ﬁve hours with 77 scans acquired every four min after
the addition of endopeptidase Lys-C. All spectra were corrected
for buffer contribution, concentration corrected (A280 reading)
and the CD values (mdeg) converted to mean residue ellipticity
(deg cm2 dmol−1 residue−1).2.5. Non reducing SDS-PAGE
Samples were analyzed by SDS-PAGE on 4–20% Tris-Glycine
Mini Protein Gels from Novex®, Introgen (Paisley, Renfrewshire,
1 l and Biomedical Analysis 123 (2016) 162–172
U
d
s
p
a
f
f
h
f
B
g
r
3
3
w
d
d
d
t
r
j
w
t
t
d
T
w
i
p
F
f
6
b
s
i
f
a
w
T
a
c
F
b
a
t
u
S
t
a
d
w
r
s
b
e
f
ﬁ
a
Time (min)
C
ou
nt
s
s-
1
(x
10
6 )
20 30 40 50 60
0
1
2
3
4
5
*
**
mAb1
A
Time (min)
C
ou
nt
s
s-
1
(x
10
6 )
20 30 40 50 60
0
1
2
3
4
5
T = 0 hours T  = 1 hours T  = 2 hours
T = 3 hours T  = 4 hours T  = 5 hours
**
*
mAb1-deg
B
Fig. 1. Limited proteolysis peptide maps of mAb1 and mAb1 – deg at a range of
digestion times. Total ion chromatograms of limited proteolysis peptide mapping
time course of: mAb1 (A) and mAb1-deg (B). Color of traces and time of digestion
step as indicated. *Peak of peptide HC[362–371]-HC[416–440], **peak of peptide64 C. Perrin et al. / Journal of Pharmaceutica
K) under non-reducing conditions. 100 mM 1-Ethylpyrrole-2,5-
ione (NEM) from Sigma Aldrich (Gillingham, Dorset, UK) in 5 mM
odium acetate from Fisher (Loughborough, Leicestershire, UK)
H = 4.5 was used to reduce the appearance of the halfmer by
lkylation of the free cysteine residues. Electrophoresis was  per-
ormed at 125 V for 2 h. Mark 12 MW molecular weight standards
rom Invitrogen (Paisley, Renfrewshire, UK), 2X 2-Amino-2-
ydroxymethyl-propane-1,3-diol (Tris)-Glycine SDS Sample Buffer
rom Invitrogen (Paisley, Renfrewshire, UK), Tris-Glycine Running
uffer from Invitrogen (Paisley, Renfrewshire, UK) were used. The
el was stained with Coomassie SimplyBlueTM SafeStain from Invit-
ogen (Paisley, Renfrewshire, UK).
. Results
.1. Digestion time course
Limited proteolysis with peptide mapping of the samples
as performed by enzymatic digestion using Lys-C under non-
enaturing and non-reducing conditions. The products of this
igestion were then analyzed by liquid chromatography coupled to
etection using UV absorbance and ESI-MS. The time of the diges-
ion was considered to be a critical parameter in obtaining optimal
esults. To establish the length of time that samples were to be sub-
ected to enzymatic digestion throughout this study, two samples
ere analyzed over a time course of ﬁve hours, with samples being
aken every hour and quenched with acid to prevent further diges-
ion. The samples analyzed were mAb1 and mAb1 that had been
eglycosylated (hereafter referred to as mAb1-deg).
The chromatograms from the time course are shown in Fig. 1.
he intensity of the peaks from antibody fragments increased
ith the time of digestion for both samples. The peak intensities
ncreased faster in the mAb1-deg sample than the mAb1 sam-
le, see Fig. 1. Small peptides were clearly separated as shown in
ig. 1, however due to sub-optimal chromatographic conditions
or separation of larger antibody fragments, the resolution after
5 min  decreases. The peaks after 65 min  correspond to large anti-
ody fragments such as intact antibody and F(ab)2. When the mass
pectrometry data was included it was possible to determine the
dentity of the peaks in the chromatograms, as well as allowing
urther separation of the peaks in the m/z  dimension. The peak
ssignments for the two chromatograms are shown in Fig. S1.
Mass spectrometry data allowed the identiﬁcation of species
ith molecular weights up to the F(ab)2 and the intact antibody.
he retention times of the intact antibody and large fragments such
s F(ab)2 was greater than 65 min. The peptides observed in the
hromatogram with elution time less than 65 min  were from the
c region. These peptides covered 90% of the heavy chain sequence
elow the hinge. These peptides were mapped on an IgG4 structure
s shown in Figs. S2–S4. For each sample the peak areas of all iden-
iﬁed peptides were calculated from the mass spectrometry data
sing extracted ion chromatograms at each time point, see Figs.
2–S4. Two examples have been plotted in Fig. 2. One of the pep-
ides HC[250–289]-HC[322–323] was from the CH2 domain of the
ntibody and the second HC[362–371]-HC[416–440] from the CH3
omain. The digestion time course proﬁles for these two  peptides
ere typical of peptides from the CH2 and CH3 domains. The rate of
elease of the two peptides from the antibody, as inferred by mea-
urement of their peak areas in the chromatograms, was different
etween the two  samples. The differences in the peak areas were
vident from the earliest time points. Both peptides were formed
aster in the digestion of the mAb1-deg samples, however, after
ve hours the signal was similar between the samples. All peptides
nalyzed were found to be released faster in the mAb1-deg sample.HC[250–289]-HC[322–323]. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the web version of this article.)
The peak areas of the peptides from the CH2 domain of the
mAb1 sample increased almost linearly from not detected at the
0 h to the 5 h shown in Fig. S2. For peptides from the CH2 domain
of the mAb1-deg sample the peak area typically increased from
not detected at 0 h to their maximum peak area after 1 h and then
remained at that level until the 5 h time point. The maximum peak
areas for the peptides from the CH2 domain in the mAb1 and mAb1-
deg samples were similar after 5 h of digestion. The behavior of
peptide HC[290–318] was different to other peptides of the CH2
domain, see Fig. S3, as it contained a missed cleavage peptide. Its
signal increased rapidly, as for other CH2 domain peptides in the
mAb1-deg sample, however, this was followed by a decrease due to
the peptide being digested to HC[292–318]. HC[292–318] showed a
slower increase in intensity than other peptides of the CH2 due to its
slower cleavage from HC[290–318]. These two peptides also con-
tained the glycan moiety of the heavy chain at residue Asn 298 and
so were detected as the glycosylated variants in the mAb1 sample
and the deamidated variants in the mAb1-deg samples. An incon-
sistency was  observed in the data for the C-terminal heavy chain
peptide HC[441–448] of the mAb1 sample after one hour of diges-
tion, this peptide appeared to be fully released at this time point
but not at later time points. All other peptides for this sample at this
C. Perrin et al. / Journal of Pharmaceutical and Biomedical Analysis 123 (2016) 162–172 165
Fig. 2. Formation of peptides with respect to time for mAb1 and mAb1-deg. (A) Location of peptide HC[250–289]-HC[322–323], HC[250–289] is indicated in red and
HC[322–323] is indicated in blue for both heavy chains of the crystal structure of an IgG4 (PDB 5DK3) [32]. (B) Peak area of peptide HC[250–289]-HC[322–323] with respect
to  time of digestion in mAb1 and mAb1-deg. (C) Location of peptide HC[362–371]-HC[416–440], HC[362–371] is indicated in blue and HC[416–440] is indicated in red for both
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s  referred to the web version of this article.)
ime point were consistent with their release proﬁles at later time
oints. One possible explanation for this is may  be that the release
f this peptide is dependent upon a structural conformation of the
c, which is very sensitive to the solution condition. Small differ-
nces in these for this sample may  have resulted from the rapid
elease of this peptide for this sample compared to others.
The peak areas of peptides from the CH3 domain of the mAb1
ample increased almost linearly, but after 1 h of digestion, rather
han from the 0 h time point as for the CH2 domain shown in Fig. S4.
he peak areas of the peptides of the CH2 domain of the mAb1-deg
ample increased faster than for the mAb1 sample and reached a
aximum value after approximately 3 h. The rate of proteolysis of
oth the CH2 and CH3 domains were faster when the sample had
een deglycosylated. The proteolysis of the CH2 domain appeared
lmost complete within the ﬁrst hour for the deglycosylated sample
hile the proteolysis of the CH3 domain appeared complete after
 h.
The digestion of the samples with respect to time was  also ana-
yzed using non-reducing SDS-PAGE. This allowed the size of the
ntibody fragments generated by the enzymatic digestion to be
easured. A degree of relative quantitation of the ‘intact’ antibody
nd fragments was also possible. Three main bands were observed
n the SDS-PAGE analysis of the mAb1 digests, see Fig. 3 and detailed362–371]-HC[416–440] with respect to time of digestion in mAb1 and mAb1-deg.
ctively. (For interpretation of the references to color in this ﬁgure legend, the reader
in Table 1. These bands were assigned as intact mAb1, F(ab)2 and an
intermediate between mAb1 and F(ab)2 the identity of which has
yet to be determined. The assignments were based on their appar-
ent molecular weight and the speciﬁcity of Lys-C toward cleavage
after the hinge to produce F(ab)2. Differences in the non-reducing
SDS-PAGE proﬁles between the two  samples were apparent from
the earliest time points, with the deglycosylated sample digesting
to F(ab)2 much faster than the glycosylated sample.
CD analysis of the digestion with respect to time was  undertaken
by performing the digestion in-device with the temperature main-
tained at 37 ◦C. No signiﬁcant differences were found between the
mAb1 and mAb1-deg CD spectra prior to the start of the digestion.
Upon addition of the endopeptidase Lys-C the CD proﬁles of the
two samples began to diverge, see Fig. 4. The mean residue molar
ellipticity increased between 250 and 305 nm for both samples.
However, the extent of the change was  less in the mAb1 sam-
ple than the mAb1-deg sample. There was  a gradual increase in
the mean residue molar ellipticity of the mAb1 sample with time.
Whereas, the increase in the mean residue molar ellipticity of the
mAb1-deg sample was rapid in the ﬁrst hour but changed more
slowly thereafter. After ﬁve hours the increase in the mean residue
molar ellipticity in the mAb1 sample had not reached the level of
that observed in the mAb1-deg sample.
166 C. Perrin et al. / Journal of Pharmaceutical and Biomedical Analysis 123 (2016) 162–172
Fig. 3. Non-reducing SDS-PAGE limited proteolysis digestion of mAb1 and mAb1-deg at a range of digestion times. Non-reducing SDS-PAGE limited proteolysis digestion
time  course of mAb1 and mAb1-deg (composite image, order of lanes rearranged for clarity). Sample in each lane are indicated in the ﬁgure. T0 = 0 h digestion, T1 = 1 h
digestion, T2 = 2 h digestion, T3 = 3 h digestion, T4 = 4 h digestion, T5 = 5 h digestion. Main bands as indicated: *monomer, **intermediate digestion product and ***F(ab)2.
Table 1
Densitometry of gel shown in Fig. 3.
Band Identity mAb1 mAb1 deg
T0 T1 T2 T3 T4 T5 T0 T1 T2 T3 T4 T5
* Monomer 81 13 31 21 19 7 80 2 3 2 2 2
**  Intermediatea 0 0 24 19 17 10 0 3 6 3 2 1
***  F(ab)2 0 10 25 36 41 45 0 56 69 74 77 78
Main bands identiﬁcation and % band from SDS-PAGE densitometry. T0 = 0 h digestion, T1 = 1 h digestion, T2 = 2 h digestion, T3 = 3 h digestion, T4 = 4 h digestion, T5 = 5 h
digestion.
a Intermediate digestion product of intact antibody being digested to F(ab)2.
Table 2
CVs for repeatability for mAb1 and mAb1-deg limited proteolysis peptide maps.
Peptide MS  detection UV detection
mAb1 mAb1-deg mAb1 mAb1-deg
A B C A B C A B C A B C
HC[250–289]-HC[322–323] 4.6 4.4 2.0 2.8 4.5 5.3 10.1 11.4 6.2 2.3 10.0 8.6
HC[290–318] 7.8 4.6 0.8 2.5 5.1 2.0 6.8 7.4 8.5 7.0 6.3 0.8
HC[328–335] 7.0 3.2 3.2 7.5 2.4 1.3 9.6 15.3 14.5 3.4 9.7 6.9
HC[362–371]-HC[416–440] 5.5 10.5 11.0 7.5 4.2 8.1 8.2 12.7 3.7 1.6 5.7 5.8
4.1 
C hown
w
w
r
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wHC[372–393] 5.3 0.7 10.2 10.0 
oefﬁcient of variation (CV) repeatability for mAb1 and mAb1-deg for peptides as s
The greatest difference in the peptide maps of the two  samples
as observed after two hours of digestion. Therefore two  hours
as used as the digestion time to be used to assess the method
obustness and whether the technique was capable of detecting
onformational changes induced by other stresses.
.2. Repeatability and inter-assay precisionThe repeatability and inter-assay precision of the method were
ssessed by digestion of mAb1 and mAb1-deg using two hour diges-
ions in triplicate on three separate occasions. Five peptides which
ere observed in all analyses were chosen for this purpose, the4.1 9.3 12.7 3.7 16.5 14.0 5.8
 in table on three separate occasions for n = 3 replicates.
locations of these peptides, when mapped onto the crystal struc-
ture of an IgG4 antibody are shown in Figs. S2–S4. Three of the
ﬁve peptides were from the CH2 domain and two from the CH3
domain, these ﬁve peptides had a sequence coverage of 62% of the
heavy chain below the hinge. The peak areas of these peptides in the
LC-MS and LC-UV chromatograms were measured and are shown
in Fig. 5. The coefﬁcient of variance (CV) of these, as measured on
the three replicates, is shown in Table 2. The CVs for the LC-MS
chromatograms ranged from 1% to 11% with an average of 5%, see
Table 2. The peak areas in the UV absorbance chromatograms for the
selected peaks were also integrated. The CVs  for the UV  absorbance
chromatograms ranged from 2% to 15% with an average of 8%, see
l and Biomedical Analysis 123 (2016) 162–172 167
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Fig. 4. Near UV spectra of mAb1 and mAb1-deg at a range of digestion times. Near
UV spectra of mAb1 and mAb1-deg. (A): Prior to enzyme addition mAb1 (blue),
mAb1-deg (red); (B): mAb1 (C): mAb1-deg. Color of plots as follows for (A) and (B):
without LysC (blue), 0 h digestion (red), 1 h digestion (green), 2 h digestion (purple),
3  h digestion (orange), 4 h digestion (black), 5 h digestion (brown). (For interpreta-
tion  of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)C. Perrin et al. / Journal of Pharmaceutica
able 2. For all samples and for all peptides, when the measurement
as performed using UV detection or MS  detection, the peak area
easured for the deglycosylated sample was signiﬁcantly greater
han the control (p-value <0.01 for MS  detection and <0.05 for the
V detection). When the peak areas were compared across the
hree occasions, the UV data was found to be more consistent than
he mass spectrometry data, as might be expected. However, a con-
rol or reference standard is always run to which the sample of
nterest is compared, therefore the ratio of a peptide’s peak area in
he sample and the control is the more appropriate variable to be
ompared across the different occasions, as shown in Fig. 6. This
atio was found to be consistent across the three occasions for each
f the peptides with a CV that ranged from 1% to 15%, with an aver-
ge of 6% for the MS  data and a CV that ranged from 3% to 21%, with
n average of 9% for the UV data. This ratio was also signiﬁcantly dif-
erent to that of unity for all peptides on all occasions with UV and
S detection, see Fig. 6. The peak area ratios measured for the UV
nd the MS  data were also found to be broadly comparable with the
xceptions of HC[290–318] and HC[362–371]-HC[416–440]. The
ormer peptide is the site of glycosylation, and so is detected in
ts glycosylated form in the mAb1 sample and its deamidated form
n the deglycosyalted sample. The MS  measurement is affected to
 greater extent than the UV measurement by the removal of the
lycan moiety. The ratio of peptide HC[362–371]-HC[416–440] was
lso found to vary between the MS  and the UV measurement, how-
ver, there were overlapping peptides in the chromatogram, which
ould have affected the measurement in the UV detection.
.3. Other molecules
To evaluate the potential of the method to detect structural
hanges, two other samples were analyzed, mAb1 that had been
ildly denatured using 2 M urea (mAb1-den) and a failed batch
f mAb1 (mAb1-r) that showed increased levels of halfmer. In
ach case the sample under investigation was  run alongside
Ab1, which was used as a control. The chromatograms obtained
rom mAb1-den and mAb1-r samples, when compared to their
espective controls, showed an increase in signal intensity and a
ifferent proﬁle, see Fig. 7. The peak areas of peptide HC[250–289]-
C[322–323] (disulﬁde linked peptide) were integrated from the
ass spectrometry data and are plotted in Fig. 8. The peak areas
easured for the mAb1 sample were different to those measured
or the mAb1-den and for the mAb1-r sample, for the peptide shown
nd for the majority of the peptides analyzed. Peptides from the
ab domain were also detected in mAb1-den but not from the
Ab1 control sample, the locations of these in a crystal structure
f an IgG4 are shown in Figs. S5 and S6. In Fig. 7B the peaks in the
hromatogram between 58 and 65 min  were identiﬁed as being
ssociated with the CH3 domain of the Fc. Lysine residue 341 of
he heavy chain is on an exposed loop between the CH2 and CH3
omains. Cleavage of heavy chain at this residue give a large pep-
ide HC[342–447], the C-terminal peptide is also be cleaved to give
nother large peptide HC[342–440]. The difference between the
wo control samples is thought to be due to inconsistent sample
torage. Sample mAb1-r and its control were subjected to an addi-
ional freeze/thaw than mAb1-den and its control, which may  have
esulted in subtle structural differences in the Fc which were sub-
equently revealed in the peptide mapping results.mAb1-den and
Ab1-r were analyzed by non-reducing SDS-PAGE, see Fig. 9. The
ontrol and the mAb1-den had similar proﬁles prior to digestion.
fter two hours of limited proteolysis digestion there were differ-
nces between the samples, see Fig. 9. The mAb1-den digests had
ower levels of monomer and digestion intermediate and increased
evels of F(ab)2 compared to the control. The mAb1-r had a different
DS-PAGE proﬁle after digestion than the control and was found to
ontain elevated levels of halfmer prior to digestion. Densitometry
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nalysis showed that the halfmer was largely digested as there was
 substantial reduction in the intensity of the corresponding band.
The mAb1-den and mAb1-r samples were also analyzed using
D. When the CD spectra of the undigested mAb1, mAb1-den and
Ab1-r were compared, no signiﬁcant differences were observed,
ee Fig. 10 for mAb1 and mAb1-den (data not shown for mAb1-
). After addition of the endopeptidase Lys-C, the CD proﬁles of
he denatured sample proﬁle diverged from the mAb1 proﬁle, see
ig. 10. After three hours of digestion, the rate of change in the CD
roﬁle was reduced, see Fig. 10. The mAb1-r sample and its control
ad similar CD proﬁles at each of the time points. The proﬁles of
he two samples overlaid within one standard deviation at each of
he time points.
. Discussion
Proteolytic digestion requires unfolding of the substrate, as the
rotein chain must adopt a conformation that can interact with
he active site of the enzyme, consequently folded and unfolded
roteins have very different proteolytic susceptibilities [22–24].
roteolysis of a folded protein under non-denaturing conditions
ccurs through transient local unfolding events, with the rate of
igestion being limited by the requirement of the enzyme to inter-
ct with these events. Alteration of the protein’s native structure
hrough covalent modiﬁcation or misfolding results in a greatereptides detected by mass spectrometry (n = 3). Peptides as indicated in (A): mass
eviations.
rate of local scale unfolding, which in turn results in a greater rate
of digestion. The locations of unfolding events within the structure
of the protein are inﬂuenced by the speciﬁc stress or modiﬁcations
that a molecule has experienced. This inﬂuences the resulting pro-
teolytic degradation of the protein, as proteolysis will be directed
toward the less stable parts of the protein’s structure. Proteoly-
sis will clearly further destabilize the protein’s structure resulting
in more rapid degradation of the remaining structure. The rate
of proteolysis is determined by the concentration of the prote-
olytic enzyme and the concentration of the protein that is in a
state that is amenable to digestion. However, the concentration
of the proteolytic enzyme is reduced with time due to autolysis
and the concentration of the protein that is amenable to diges-
tion is also reduced as it is depleted by digestion. Therefore, it was
expected that the extent of digestion would plateau as a result of
these factors. Other factors, such as aggregation and solubility of
the digestion products can also affect the digestion.
The non-denaturing digestion of mAb1 and mAb1-deg were
demonstrated to occur at different rates using peptide mapping,
CD and SDS-PAGE vide supra. For both samples the digestion prod-
ucts were found to be the result of proteolysis of the Fc domain.
The CH2 domain of the deglycosylated sample was  found to be
more susceptible to proteolysis than the CH3 domain. Deglyco-
sylated Fc compared to glycosylated Fc is structurally less stable,
especially in the CH2 domain, as described previously [26] and was
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tandard deviations.
herefore expected to be more susceptible to digestion. Digestion of
he CH2 domain would destabilize the CH3 domain resulting in the
ore rapid digestion of this domain. Removal of the glycans may
lso allow greater access of the proteolytic enzyme to potential
leavage sites. The Fab structures were expected to be essentially
he same in both mAb1 and mAb1-deg [27]. The differences in the
igestion proﬁles were also found to reduce when longer diges-
ion times were used. The rationale for the difference in digestion
etween the glycosylated and deglycosylated sample was that the
c became less stable upon deglycosylation resulting in an increase
n the rate of digestion [26–29]. However, the eventual concen-
ration of the released products was similar in both cases, hence
he requirement to select the optimum digestion time. The pep-
ide maps of mAb1 and mAb1-deg were expected to be different,
ven if the structural change induced by the deglycosylation had no
ffect on the proteolysis, due to the differing retention times of the
lycopeptides compared their deglycosylated counterparts. When
eaks associated with glycopeptides were discounted differences
n the chromatograms were still evident due to the different rates
f proteolysis of the two samples.
Evaluation of the digestion time course using SDS-PAGE
evealed that, as detailed in Table 1, the mAb1-deg sample was
apidly digested to give F(ab)2 and smaller peptides, while the
Ab1 sample was digested more slowly to F(ab)2, and higher lev-
ls of F(ab)2 with intermediates between the intact antibody and
(ab)2. The Fc of the mAb1-deg sample was digested to smaller
eptides much more rapidly than in the mAb1 sample, with the
ntermediates not observed at such high levels. These analyses
ndicated that the Fc was predominantly being digested to smaller
eptides by the Lys-C.
Analysis of the mAb1 sample and the mAb1-deg sample using
D did not readily reveal any structural differences between the
wo samples prior to addition of the proteolytic enzyme. Upon
ddition of the proteolytic enzyme to the samples the CD proﬁles
ere observed to change. The changes were more apparent and
f a greater magnitude in the mAb1-deg sample. This correlated
ith the results of the peptide mapping and the SDS-PAGE analysis,
hich showed the Fc of the mAb1-deg sample to be digested fastered peptides with MS  and UV detection as shown in ﬁgure. Error bars indicate two
than the Fc of the mAb1 sample. This was  an interesting observation
as structural differences that were not obvious using CD analysis
prior to digestion were clearly revealed upon digestion.
The limited proteolysis and peptide mapping results for the
mAb1 and mAb1-deg samples demonstrated that the two  samples
could be clearly differentiated for the earlier time points, with the
differences greatest after about two  hours of digestion. Plotting the
peak areas of selected peptides with respect to the time of diges-
tion showed that the rate of release of these peptides was different
for the two  samples. The results of the SDS-PAGE and CD mea-
surements also demonstrated that the proteolysis occurred more
rapidly for the mAb1-deg sample. These results indicated that the
digestion difference resulted from changes in the protein’s higher
order structure and that the technique was  capable of detecting
such differences.
For the limited proteolysis and peptide mapping method to
have utility in determining sample comparability, or lack thereof,
it was required that it consistently distinguish between samples
with differing higher order structures. Therefore the repeatability
and intra-assay precision of the method was assessed by analysis
of the mAb1 and mAb1-deg samples in triplicate (three separate
preparations) on three occasions. On all three occasions the mAb1
and mAb1-deg samples the chromatograms were visually different
and the peak areas of the selected peaks were signiﬁcantly different
between the two samples, vide supra. This was the case whether the
detection was by UV or MS.  For corresponding peptides in the two
samples, the ratio of their peak areas were found to be consistent
between the occasions when the method was performed, which
further demonstrated the robustness of the method. The average
of the CVs  of the measured ratios by MS  detection was found to be
5.7%, which further indicated that the method has potential to be
used in the biopharmaceutical industry as a characterization tool,
and with further development as a QC method. The variability of
the results was  found to be greater when UV detection was  used
(CV = 9.0%). This was  attributed to the relatively low signal that was
measured by this method of detection. This has the potential to
be improved signiﬁcantly, for example by use of higher capacity
HPLC columns and injection of larger amounts of sample. Increased
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Fig. 7. Limited proteolysis peptide maps of mAb1, mAb1-den and mAb1-r. Limited
proteolysis peptide maps of mAb1 and mAb1-den (A) and mAb1 and mAb1-r (B).
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Fig. 8. Peak areas of peptide HC[250–289]-HC[322–323] in mAb1, mAb1-den
and  mAb1-r. Peak areas measured by MS  detection of peptide HC[250–289]-
HC[322–323] in mAb1 and mAb1-den (A) and mAb1 and mAb1-r (B). Error bars
indicate two standard deviations.
Fig. 9. Non-reducing SDS-PAGE limited proteolysis digestion of mAb1, mAb1-denigestion time was  2 h. Total ion current is shown as indicated in ﬁgure. *Peptide
C[362–371]-HC[416–440].
hromatographic resolution may  also increase the observed sig-
al, and could be achieved using triﬂuoroacetic acid rather than
ormic acid in the mobile phase, using a different column temper-
ture or using different column chemistries. The observed signal
as lower than that observed when performing peptide mapping
ith fully reduced and denatured samples. This is consistent with
he digestion being incomplete. The mass spectrometric detection
ad higher sensitivity than the UV detection. Consequently, it was
ossible to detect more peaks in the mass spectrometry data than
n the UV data. The absolute peak areas of the peptides of interest
ere found to have a higher variability across the different occa-
ions on which the assay was run for the MS  data, as was expected
ue to the wide range of factors that affect the sensitivity of the MS
etection. This highlighted the beneﬁt of using a control sample
o which other samples can be compared to. The ratio of the peak
reas in the sample and control were found to be more consistent
cross the occasions when the samples were analyzed.
The applicability of the technique was further assessed by appli-
ation to two additional cases, a mildly denatured sample and a real
orld example of a batch that failed to make speciﬁcations, due
o the batch being partially reduced. Urea is often used to unfold
roteins, the use of 2 M urea solution was considered sufﬁcient
o expose folded features of the sample without causing complete
nfolding of the antibody. Partial reduction of the disulphide bonds
f the hinge has been shown to affect the overall stability of the
ntibody, with the CH2 domain predominantly impacted as a resultand mAb1-r. Non-reducing SDS-PAGE limited proteolysis digestion of mAb1, mAb1-
den  and mAb1-r without digestion (T0) and after 2 h (T2) of limited proteolysis
digestion (composite image, order of lanes rearranged for clarity).
of the enhanced ﬂexibility of the hinge [30,31]. On both occasions
the limited proteolysis peptide maps of the samples were visually
different from controls, as shown in Fig. 7 and there were signif-
icant differences in the intensities of selected peptides, see Fig. 8.
This demonstrated the suitability of the limited proteolysis pep-
tide mapping method to be applied to a wider range of samples
for which a structural change had been induced. Although the pre-
dominant differences observed here have resulted from differences
in digestion of the Fc, peptides from the Fab domains were also
observed for the mAb1-den sample demonstrating that changes in
the structure of this region will also result in detectible changes in
the peptide maps.
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eader is referred to the web  version of this article.)
Investigation of the limited proteolysis digestion of the addi-
ional two samples using SDS-PAGE and CD also showed that the
igestion occurred more rapidly in the structurally altered samples.
DS-PAGE conﬁrmed that it was the Fc that was preferentially being
igested and at a higher rate in the deglycosylated and denatured
amples, and that the halfmer was being digested more rapidly
han the intact antibody. CD conﬁrmed that there was a greater
ate of digestion occurring in the deglycosylated and denatured
ample, but did not detect any change in the halfmer sample. It is
nown that CD has limitations in terms of the structural changes
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that are detected and the level at which such changes are evident.
These studies demonstrated that the limited proteolysis digestion
of a sample followed by analysis by CD increased magnitude of the
difference in the CD spectra compared to a similarly treated refer-
ence. The increased difference was found to be due to the increased
susceptibility to proteolysis of the structurally altered samples. A
similar effect was  also observed in the SDS-PAGE analysis of the
samples digested under non-denaturing conditions. These were
interesting ﬁndings as it indicates a manner in which the sensitivity
of these techniques to structural change can be increased.
5. Conclusions
Limited proteolysis and peptide mapping has been demon-
strated to have potential to be more widely used in the
biopharmaceutical industry for comparability of samples in terms
of their higher order structure. It is a relatively simple technique
to implement, potentially simpler than traditional peptide map-
ping as fewer steps are required in the sample preparation. The
simplicity of its implementation also offers advantages over other
techniques for analysis of higher order structure, such as HDX. It
was demonstrated that the method could detect a range of struc-
tural changes, including a real world example of a failed batch. The
repeatability and intra-assay precision of the method were assessed
and it was demonstrated that the performance of the method was
acceptable. It was found that limited proteolysis combined with
CD and SDS-PAGE increased the sensitivity of these techniques to
structural change, compared to a control sample.
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